#South Korea #Seoul #PCR Testing #Seegene #CURECA™

Seegene to Launch CURECA™: A Revolutionary Automated PCR Solution Set to Transform Diagnostics

Seegene Inc., a leading figure in molecular diagnostics (MDx), has unveiled an ambitious plan to innovate laboratory automation through its upcoming product, CURECA™. This next-generation system is designed to fully automate Polymerase Chain Reaction (PCR) testing workflows, enhancing efficiency and reducing the need for manual intervention.

What is CURECA™?

CURECA™ stands for Continuous Unlimited Random-access Expandable and Customizable full Automation. This pioneering system aims to streamline PCR processes, making them more accessible and easier to manage in clinical settings. The complete workflow, from sample pre-processing to result analysis, will be handled by this automated solution, reimagining the traditional laboratory dynamics.

The system features two main components:

• - Customizable Pre-treatment System (CPS): This segment is responsible for the initial sample handling and preparation.
• - Customizable and Expandable Full Automation (CEFA): This unit conducts the entire PCR setup, from sample loading to gene amplification and final result analysis.

Addressing Automation Challenges

One of the critical challenges within MDx has been the labor-intensive process of pre-treatment that requires trained professionals to manage various specimen types, including stool, urine, blood, and sputum. CURECA™ is set to tackle these challenges through the CPS, automating essential steps such as sorting, centrifugation, and heating treatments. Notably, CPS can operate independently from CURECA™, making it versatile enough to be utilized in various laboratory testing sectors like hematology and biochemistry.

Seegene's design approach ensures that CURECA™ is modular, offering laboratories flexible configuration based on individual operational needs. This adaptability serves to minimize human error, enhance accuracy, and enable nonstop, high-throughput PCR testing, operating 24/7.

Future Debut at ESCMID Global 2025

The grand introduction of CURECA™ will be showcased through a conceptual video at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) from April 11-15 in Vienna, Austria. This presentation will highlight the envisioned automation workflow and further clarify how it can be tailored to various lab ecosystems.

Dr. Jong-Yoon Chun, Seegene's founder and CEO, expressed his aspirations for CURECA™ in redefining MDx. He stated, "Until now, there has been no system capable of fully automating pre-treatment processing for various specimen types, which has limited true automation in MDx. We aim to define a new global benchmark in PCR testing."

Supporting a Global Health Vision

CURECA™ is more than just a product; it reflects Seegene's commitment to a future free of diseases. The system supports the company’s global initiative to make advanced MDx technologies accessible worldwide, ultimately improving healthcare integration. By enhancing diagnostic processes, CURECA™ strives to fulfill the vision of a healthier world without the fear of infectious diseases.

Seegene will also present its syndromic real-time PCR assay portfolio under the theme “Redefining MDx” at ESCMID Global 2025, showcasing validated tests designed to meet evolving diagnostic needs, especially in light of antimicrobial resistance and post-COVID-19 healthcare challenges.

With over 20 years of expertise in PCR technologies, Seegene’s wide-reaching impact has been notably propelled during the COVID-19 pandemic, providing millions of tests globally. CURECA™ is slated to be another key development that aims to further this mission—a move towards a world where healthcare is effective, rapid, and automated.

In summary, Seegene's CURECA™ project holds promise for the transformation of PCR testing, aiming for smarter laboratories and healthier lives worldwide. The anticipated demonstrations over the coming year are sure to capture the attention of the medical and diagnostic communities as they look forward to deploying cutting-edge technology in laboratories across the globe.